Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level

iFIT is a trial for newly diagnosed transplant-ineligible patients with the bone marrow cancer myeloma. These patients are generally older and have a lower level of fitness than others. Patients can take part if their doctor would otherwise recommend the standard NHS treatment daratumumab, lenalidomide and dexamethasone (DRd). After six months of DRd, the subsequent treatment a patient receives in iFIT is based on two factors: the patient's fitness level and treatment response. The trial compares different treatment strategies to determine whether outcomes can be improved for specific patient

Trial Details

NCT ID
NCT07649525
Phase
PHASE3
Sponsor
University of Leeds
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Daratumumab
  • Lenalidomide
  • Dexamethasone
  • Teclistamab
  • Talquetamab
Locations (sample)
  • Bristol, United Kingdom|51.45523,-2.59665
  • Eastbourne, United Kingdom|50.76871,0.28453
  • Leeds, United Kingdom|53.79648,-1.54785
  • Liverpool, United Kingdom|53.41058,-2.97794
  • London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • Newly diagnosed as having symptomatic MM, plasma cell leukaemia or non-secretory MM according to IMWG diagnostic criteria 2014.
  • Considered not suitable to receive autologous stem cell transplant as part of their first line therapy by the treating clinician,
  • Planned for treatment with Daratumumab, Lenalidomide and dexamethasone (DRd) as first line therapy as standard of care,
  • Aged 18 years or greater,

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →